AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03069391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise alone (PES) first
Description: following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
Study NCT03069391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive exercise alone (iCE) first
Description: following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
Study NCT03069391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interactive Physical and Cognitive Exercise (iPACES™)
Description: following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
Study NCT03106259 — intervention group
Intervention type: DRUG
Intervention: FURESTEM-RA Inj.
Description: Non-interventional observational study
Study NCT03437525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
Study NCT02331836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arc Endocuff (AEC 110, 120, 130, 140)
Study NCT02331836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap
Description: Olympus Disposable distal attachment 15mm diameter, 4mm depth
Study NCT02331836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscope
Study NCT01949350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
Study NCT01949350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate protein
Description: Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
Study NCT01949350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starved
Description: Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
Study NCT02242409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Abraxane
Description: Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
Study NCT02970409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saline
Description: catheter lock using saline
Study NCT02970409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: catheter lock using Heparin
Study NCT01606345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valrubicin
Description: Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
Study NCT05691296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home training
Description: Letter Chart Accomodative Rock Training for 2 minutes each time
Study NCT05691296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School training
Description: Letter Chart Accomodative Rock Training for 2 minutes each time
Study NCT01392976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
Study NCT01392976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Intravenous Lidocaine Infusion
Description: Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative Intravenous Lidocaine Infusion
Description: Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative Pregabalin
Description: Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Pregabalin
Description: Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Pregabalin Placebo
Description: Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perioperative Pregabalin Placebo
Description: Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraoperative Intravenous Lidocaine Placebo Infusion
Description: Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
Study NCT02240199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Intravenous Lidocaine Placebo Infusion
Description: Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
Study NCT01312688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Goal Directed Hemodynamic Therapy in Sepsis
Description: Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
Study NCT01312688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Goal Directed Hemodynamic Therapy in Sepsis
Description: Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
Study NCT02568150 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single group, open-label
Study NCT03249233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZenLens™
Description: The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Study NCT03249233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zen™ RC
Description: The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Study NCT00387075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: [123I]β-CIT and SPECT imaging
Description: This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
Study NCT00387075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]β-CIT
Description: SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
Study NCT00887224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate sustained release 50 mg
Description: 50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
Study NCT00887224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate sustained release 25 mg
Description: 25 mg tablet for taper, once daily for 1 week
Study NCT00887224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
Study NCT04295642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVL-751
Description: Oral tablet
Study NCT04295642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-751
Description: Oral tablet
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01555138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol is delivered via a SDDPI.
Study NCT01555138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol/fluticasone is delivered via a MDDPI
Study NCT03779672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride 10 mg
Description: * Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps
Study NCT03779672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine Hydrochloride 10 mg
Description: * Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps
Study NCT02117310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
Study NCT04061759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.
Description: Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
Study NCT03244800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously once daily for 49 days.
Study NCT03244800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously once daily for 49 days.
Study NCT02103166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine bromide
Description: 20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
Study NCT02103166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: 100 ml of physiological serum (0.9% NaCl).
Study NCT02903875 — intervention group
Intervention type: OTHER
Intervention: Patient therapeutic education (PTE) programme
Study NCT03970096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration/biopsy
Study NCT03970096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03970096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03970096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole 1 mg tablets for oral use QD continuously
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole 1 mg tablets for oral use QD continuously
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg tablets for oral use QD continuously
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg tablets for oral use QD continuously
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
Study NCT03822468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
Study NCT01098604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 32mm ceramic head group
Description: we performed THA using 32mm ceramic head in this group.
Study NCT03164096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
Study NCT01220882 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Radiographic skeletal age assessment
Description: bone age assessment from the elbow lateral radiograph
Study NCT01967251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil tablets
Study NCT01967251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Udenafil placebo-matching tablets
Study NCT01384968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beetroot juice
Description: 170 mL beetroot juice (Beet It, James White drinks Ltd).
Study NCT01384968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beetroot juice
Description: 170 mL beetroot juice (Beet It, James White drinks Ltd).
Study NCT00221598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemodialysis with different dialysate temperatures
Description: Haemodialysis with different dialysate temperatures is used.
Study NCT02446990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: 5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
Study NCT02446990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
Study NCT00323115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell
Description: Vaccine given by cervical lymph node injection 3 times every other week
Study NCT00323115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
Study NCT00323115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT is standard of care (SOC) post surgery
Study NCT00323115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Vaccine given cervical lymphnode injection 3 times every other week
Study NCT02894931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monosaccharides
Description: The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
Study NCT02894931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: monosaccharides
Description: The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
Study NCT02894931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Disaccharides
Description: The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
Study NCT01006057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
Study NCT01006057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
Study NCT01006057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
Study NCT01006057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
Study NCT02894931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acids
Description: The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
Study NCT02894931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificial Sweeteners
Description: The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
Study NCT02894931 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control- water
Description: Chilled water flavored with lemon juice as control
Study NCT01006057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
Study NCT03258398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: eFT508 will be taken orally (PO) twice a day (bid).
Study NCT03258398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter